UBS O'Connor’s Spero Therapeutics SPRO Stock Holding History

UBS O'Connor’s Portfolio SPRO Stock Details SPRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-168,018	Closed	-$1.03M	–	123
2018 Q4	$1.03M	Sell	168,018 -1,982	-1%	-$16.1K	0.04%	164
2018 Q3	$1.79M	Buy	+170,000	New	+$1.97M	0.04%	176

Other funds holding SPRO

Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS O'Connor's SPRO Position: Q1 2019 in Review

UBS O'Connor sold out of Spero Therapeutics (SPRO) in Q1 2019, closing a stake of 168,018 shares — an estimated $1.03M sold.

UBS O'Connor first reported a position in SPRO in Q3 2018 and held it in 2 quarters. The position peaked at $1.79M in Q3 2018. 55 funds tracked by Wall St. Rank hold SPRO as of Q1 2019.

UBS O'Connor reported no remaining Spero Therapeutics position as of Q1 2019 after selling out during the quarter.
UBS O'Connor sold 168,018 Spero Therapeutics shares in Q1 2019, an estimated $1.03M.
UBS O'Connor first reported a position in Spero Therapeutics in Q3 2018 and held it in 2 quarters.
UBS O'Connor's Spero Therapeutics position peaked at $1.79M in Q3 2018.
55 funds tracked by Wall St. Rank held Spero Therapeutics as of Q1 2019.

Based on UBS O'Connor's 13F filing for Q1 2019, filed 13 May 2019.